INFLUENCE OF CYP3A5 GENOTYPE ON THE PHARMACOKINETIC PROFILE OF TACROLIMUS IN PAEDIATRIC TRANSPLANT PATIENTS

被引：0
|
作者：
McLean, K.
Fung, A.
Gijsen, V.
Nalli, N.
Safi, M.
Daljevic, T.
Ogaki, C.
Mital, S.
机构：
来源：
CANADIAN JOURNAL OF CARDIOLOGY | 2012年 / 28卷 / 05期
关键词：
D O I：
10.1016/j.cjca.2012.07.471
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：S291 / S291
页数：1
相关论文
共 50 条
  • [41] CYP3A5 GENOTYPE AND TACROLIMUS DOSING REQUIREMENTS IN RENAL TRANSPLANT. CASE REPORT.
    Belen Martinez-lopez, Ana
    Blanco, Olalla Alvarez
    Lopez-fernandez, Luis A.
    Fernandez-llamazares, Cecilia M.
    Manrique-rodriguez, Silvia
    Barraca Nunez, Daniel
    Luque De Pablos, Augusto
    PEDIATRIC NEPHROLOGY, 2015, 30 (09) : 1726 - 1726
  • [42] Impact of CYP3A5 Genotype on Tacrolimus Dosing Requirements and Trough Concentrations in Cardiac Transplant Recipients
    Wu, Yanting
    Eadon, Michael T.
    Schenkelberg, Laurie
    Rao, Roopa A.
    Skaar, Todd C.
    Tillman, Emma M.
    Shugg, Tyler A.
    PHARMACOGENETICS AND GENOMICS, 2025, 35 (01): : 20 - 20
  • [43] CYP3A5 genotype does not influence the blood concentration of tacrolimus measured with the Abbott immunoassay
    Moreton, M
    Fredericks, S
    McKeown, DA
    Shiferaw, EW
    MacPhee, LAM
    Johnston, A
    Holt, DW
    CLINICAL CHEMISTRY, 2005, 51 (11) : 2214 - 2215
  • [44] CYP3A5 genotype does not influence the measured blood concentration of tacrolimus with the Abbott immunoassay
    Fredericks, S
    Moreton, M
    McKeown, DA
    Shiferaw, E
    Holt, DW
    THERAPEUTIC DRUG MONITORING, 2005, 27 (02) : 247 - 247
  • [45] Impact of donor CYP3A5 genotype on pharmacokinetics of tacrolimus in South African paediatric liver transplant patients (vol 114, e1367, 2024)
    Wheeler, C.
    Masimirembwa, C.
    Mthembu, B.
    Botha, J.
    Scholefield, J.
    Fabian, J.
    SAMJ SOUTH AFRICAN MEDICAL JOURNAL, 2024, 114 (07):
  • [46] Receptor-donor CYP3A5 and CYP3A4 genotype testing in liver transplant patients and its influence in tacrolimus blood levels: a retrospective study
    Prieto, J. L. Rubio
    Macher, H.
    Bravo, M. A. Gomez
    Silva, J. L. Garcia de Veas
    Artacho, G. Suarez
    Rodriguez, A. Rodriguez
    Pozo, C. Sanchez
    Guerrero, J.
    Rubio, A.
    CLINICAL CHEMISTRY, 2024, 70 : I222 - I222
  • [47] Tacrolimus population pharmacokinetic models according to CYP3A5/CYP3A4/POR genotypes in Chinese Han renal transplant patients
    Zhu, Wan
    Xue, Ling
    Peng, Hongwei
    Duan, Zhouping
    Zheng, Xuelian
    Cao, Duanwen
    Wen, Jinhua
    Wei, Xiaohua
    PHARMACOGENOMICS, 2018, 19 (13) : 1013 - 1025
  • [48] In Vivo CYP3A4 Activity, CYP3A5 Genotype, and Hematocrit Predict Tacrolimus Dose Requirements and Clearance in Renal Transplant Patients
    de Jonge, H.
    de Loor, H.
    Verbeke, K.
    Vanrenterghem, Y.
    Kuypers, D. R.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2012, 92 (03) : 366 - 375
  • [49] Prediction of the tacrolimus population pharmacokinetic parameters according to CYP3A5 genotype and clinical factors using NONMEM in adult kidney transplant recipients
    Nayoung Han
    Hwi-yeol Yun
    Jin-yi Hong
    In-Wha Kim
    Eunhee Ji
    Su Hyun Hong
    Yon Su Kim
    Jongwon Ha
    Wan Gyoon Shin
    Jung Mi Oh
    European Journal of Clinical Pharmacology, 2013, 69 : 53 - 63
  • [50] Prediction of the tacrolimus population pharmacokinetic parameters according to CYP3A5 genotype and clinical factors using NONMEM in adult kidney transplant recipients
    Han, Nayoung
    Yun, Hwi-yeol
    Hong, Jin-yi
    Kim, In-Wha
    Ji, Eunhee
    Hong, Su Hyun
    Kim, Yon Su
    Ha, Jongwon
    Shin, Wan Gyoon
    Oh, Jung Mi
    EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 2013, 69 (01) : 53 - 63
12345